Getting better value from the NHS drug budget

BMJ ◽  
2010 ◽  
Vol 341 (dec17 1) ◽  
pp. c6449-c6449 ◽  
Author(s):  
J. C. Moon ◽  
A. S. Flett ◽  
B. B. Godman ◽  
A. M. Grosso ◽  
A. S. Wierzbicki
Keyword(s):  
Drug Budget

Organization of chemotherapeutic preparations in advance: Do we save or waste money?

2020 ◽  
pp. 107815522096798
Author(s):  
Romain-Pacôme Desmaris ◽  
Elisabeth Bermudez ◽  
Maxime Annereau ◽  
François Lemare ◽  
Florian Slimano
Keyword(s):  
Prospective Study ◽  
Data Sources ◽  
Day Hospital ◽  
Drug Budget ◽  
Positive Balance ◽  
Report Data ◽  
A Prospective Study ◽  
Extemporaneous Preparation ◽  
The Cost

Objective The development of oncology day-hospital activities contributes to increase quality of life of patients and consequently have changed their perception about waiting. The extemporaneous preparation of antineoplastic has become difficult to achieve given the increasing activity, and hospital pharmacists have taken up the challenge by the implementation of the antineoplastic preparation in anticipation. Because anticipation can lead to an important number of preparations to be discarded, we also develop a recycled process for other patients to limit these waste extra costs. We aim to demonstrate the positive balance of anticipated preparation in this 4-year study report. Data sources: This prospective study was conducted in a major European oncology day-hospital from January, 2012 to December, 2015. The data were extracted from our software WinSimbad™ and updated as needed. The number and cost-associated of preparation ungiven chemotherapy doses (recycled or discarded) were compared to the global drug budget of our hospital in order to not exceed 2%. Data summary: 303,100 antineoplastic have been prepared. Approximately 35% of them were anticipated with an average of 5,431±984 that were finally ungiven. Two-third was recycled and the cost of the ungiven preparations finally discarded represents 1.7±0.15% of the global drug budget. Conclusions This study assesses the drug wastage and its associated cost of this concept through a prospective study and discusses the cost of ungiven antineoplastic preparations. With prior consideration of the need to define the acceptable rate of discarded ungiven preparation, the hospitals with an high oncology day-hospital activity should implement this approach.

Computer-generated reports for monitoring variances in the drug budget

1987 ◽  
Vol 44 (4) ◽  
pp. 776-782
Author(s):  
Lorraine Basil Horner ◽  
Philip W. Keys
Keyword(s):  
Drug Budget

scholarly journals A Multidisciplinary Hospital-based Antimicrobial Use Program: Impact on Hospital Pharmacy Expenditures and Drug Use

1996 ◽  
Vol 7 (2) ◽  
pp. 104-109 ◽  
Author(s):  
Suzette Salama ◽  
Coleman Rotstein ◽  
Lionel Mandell
Keyword(s):  
Quality Assurance ◽  
Hospital Pharmacy ◽  
Cost Savings ◽  
Antimicrobial Use ◽  
Canadian Hospital ◽  
Drug Budget ◽  
Program Impact ◽  
Use Patterns ◽  
Antimicrobial Prescribing ◽  
Prescribing Behaviour

The authors’ hospital embarked on a three-component, multidisciplinary, hospital-based antimicrobial use program to cut costs and reduce inappropriate antimicrobial use. Initially, antimicrobial use patterns and costs were monitored for 12 months. For the next two years, an antimicrobial use program was implemented consisting of three strategies: automatic therapeutic interchanges; antimicrobial restriction policies; and parenteral to oral conversion. The program resulted in a reduction in the antimicrobial portion of the total pharmacy drug budget from 41.6% to 28.2%. Simultaneously, the average cost per dose per patient day dropped from $11.88 in 1991 to $10.16 in 1994. Overall, mean monthly acquisition cost savings rose from $6,810 in 1992 to $27,590 in 1994. This study demonstrates that a multidisciplinary antimicrobial use program in a Canadian hospital can effect dramatic cost savings and serve as a quality assurance activity of physician antimicrobial prescribing behaviour.

scholarly journals Bivalirudin Medication Use Evaluation and Cost Savings Initiative

2017 ◽  
Vol 52 (8) ◽  
pp. 522-526
Author(s):  
Adam C. Sieg ◽  
Jennifer A. Gass
Keyword(s):  
Medication Use ◽  
Cost Savings ◽  
Drug Expenditure ◽  
Common Pathway ◽  
Drug Budget ◽  
Cost Avoidance ◽  
Thrombin Inhibition ◽  
The Cost ◽  
Unique Mechanism ◽  
Inhibition Of Thrombin

Bivalirudin is a parenteral anticoagulant that elicits its effect through inhibition of both free and clot bound-thrombin. Inhibition of thrombin serves as a unique mechanism for anticoagulation when compared to heparin as thrombin serves as the final common pathway for the intrinsic and extrinsic coagulation cascades. Due to unclear benefit over heparin, concerns regarding reversibility, and most importantly cost its use as a parenteral anticoagulant varies by institution. A recent drug expenditure review within our institution noted a significant increase in the contribution bivalirudin had on the overall drug budget. In an effort to establish the rationale for the cost increase, a medication use evaluation was performed. While it was discovered that 625 out of 1364 days of bivalirudin therapy were potentially avoidable, an equally important discovery was the amount of waste that was associated with bivalirudin therapy. Calculating daily requirements for bivalirudin indicated that 60% of patients required less than 100 mg per day. Within this article, we describe a cost-savings initiative to reduce bivalirudin waste and the resulting cost-avoidance following implementation.

scholarly journals Moving Beyond the Drug Budget Silo Mentality in Europe

2003 ◽  
Vol 6 (s1) ◽  
pp. S74-S77 ◽  
Author(s):  
Michael Drummond ◽  
Bengt Jonsson
Keyword(s):  
Drug Budget
Sign in / Sign up

Export Citation Format

Share Document